Articles tagged with Breast Cancer
Researchers at the University of Melbourne identified 24 previously unknown epigenetic changes that alter a woman's risk of breast cancer and can be passed down through generations. These changes, related to DNA methylation, were found in only approximately 20% of women with familial breast cancer who underwent genetic testing.
Researchers found that patients with a history of breast cancer or lymphoma are three times more likely to develop heart failure than those without cancer. Elevated risks were associated with diabetes, high doses of chemotherapy, and anthracycline drugs.
Researchers at USC Michelson Center successfully utilize a new metal detection technique for studying cancer cells. By imaging metal-tagged antibodies on biopsies from a patient with metastatic prostate cancer, scientists can identify and characterize cancer cells in a blood sample after it is placed on a slide.
A new study of 2,000 women found no association between long-term exposure to trihalomethanes (THMs) and breast cancer risk, contradicting previous links to bladder cancer. However, high levels of chloroform were linked to a moderate association with breast cancer in some cases.
A genetic variant of mutant p53 enhanced mitochondrial function, leading to increased tumor cell metabolism and poorer prognosis for breast cancer patients. The study found that this variant was associated with faster migration and higher ability to invade and metastasize in models of lung and bone metastasis.
A study found that breast cancer patients' initial negative impressions of radiation therapy were often unfounded. The majority of patients reported that short-term side effects were less than or as expected, and long-term side effects were manageable.
Researchers at UNC and NC State developed a biodegradable hydrogel scaffold system to release combination chemo-immunotherapeutic drugs, significantly inhibiting cancer recurrence after primary tumor removal. The approach could work in other tissue types and has shown promising results in animal models.
Researchers found that increased tissue stiffness leads to tumor aggressiveness and drug resistance in breast cancer cells. The study suggests that developing drugs that can prevent stiffness may stop the spread of cancer.
Researchers developed an MRI technique that eliminates contrast agents, reducing unnecessary biopsies and detecting 98% of malignant lesions. The diffusion kurtosis imaging method provides a microscopic level picture of breast tissue, helping to clarify suspicious findings.
Researchers developed a method combining diffusion-weighted MRI with intelligent image analysis to detect malignant changes in breast tissue. The new method reduced false positive findings by 70% and accurately identified malignant tumors in 98% of cases.
Researchers found that genes responsible for metastasis can also initiate primary tumour development, driven by the fly model Drosophila melanogaster. This discovery strengthens the notion that same genes can activate tumour growth and metastasis in some tumours.
Researchers developed a liquid biopsy test to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer. The study found that 64% of patients had more than 10% tumor DNA, correlated with poor survival outcomes.
A new study published in JAMA Surgery found that breast cancer patients who undergo mastectomy with or without immediate reconstruction tend to be less satisfied than expected with their physical and sexual health post-surgery. Women who choose immediate reconstruction overestimated their satisfaction with appearance, while those who d...
A global survey of genetic testing labs reveals inconsistent protocols for analyzing BRCA genes, which could impact cancer susceptibility. The study calls for global best-practice guidelines to ensure consistency in test results.
A study of nearly 800 postmenopausal women found that four commonly used prognostic breast cancer tests have varying abilities to predict disease recurrence. The tests, including Oncotype Dx and Prosigna Risk of Recurrence Score, were compared for their accuracy in predicting whether the cancer will return after five years.
A large-scale study found a possible association between highly processed food intake and an increased risk of overall cancer, breast cancer, and lower risks of other types. The study suggests that rapid consumption of ultra-processed foods may drive a growing burden of cancer in the next decades.
Researchers at Dana-Farber Cancer Institute have identified a specific mechanism by which estrogen receptor-positive breast cancers become resistant to standard therapies and metastasize. DNA mutations in the estrogen receptor gene cause tumors to grow even without estrogen, leading to treatment-resistant disease.
A new optical imaging system uses red and near-infrared light to identify breast cancer patients who are likely to respond to chemotherapy. The system analyzes blood flow dynamics in response to a single breath hold and has been shown to correctly identify responders in 92.3% of patients.
A large study found that family history of breast cancer significantly increases the risk of developing invasive breast tumors in women aged 65 and older. The researchers suggest that women with a first-degree family history should consider continuing mammography screening even beyond age-based recommendations.
Researchers developed autonomous nanorobots that can selectively target and starve out cancerous tumors by blocking blood supply. The technology, using DNA origami, has shown safe and effective results in shrinking tumors and causing tissue death.
A study found that full integration of digital breast tomosynthesis (DBT) significantly reduced false positive rates in breast cancer screening exams. DBT was also associated with a higher cancer-detection rate compared to traditional digital mammography.
A study by the University of Louisville found that Medicaid expansion in Kentucky led to an increase in diagnosis rates of early-stage breast cancer and greater utilization of breast-conserving surgery. However, improvements in efficiency and timing of postsurgical therapy were less robust.
A European Organisation for Research and Treatment of Cancer trial found that combining a 'soft' chemotherapy with antiHER2 therapy is highly active and has low toxicity in older patients with HER2 positive metastatic breast cancer. The regimen resulted in a seven-month longer progression-free survival compared to targeted therapy alone.
Research from the Francis Crick Institute discovered that immune cells called Natural Killer cells accumulate in tumours and release chemicals attracting specialised dendritic cells. Genes associated with these cells correlated with cancer patient survival rates, suggesting a new basis for immunotherapies.
Researchers identified a new survival pathway in cancer stem cells that fuels the growth and spread of triple-negative breast cancer. The study suggests targeting this pathway may lead to new treatments for women with this aggressive subtype of breast cancer.
Women who underwent mastectomy without reconstruction underestimated their future quality of life, while those with immediate reconstruction overestimated it. The study highlights the importance of decision support for breast reconstruction, taking into account patients' expectations about well-being.
Researchers at UPMC Hillman Cancer Center have identified a new genetic change in the estrogen receptor that contributes to therapy resistance in ER-positive breast cancer. The presence of ESR1 fusion proteins in treatment-resistant breast cancer may lead to improved treatments for this form of the disease.
Researchers discovered that limiting an amino acid called asparagine can dramatically reduce breast cancer's ability to travel, suggesting a potential strategy to prevent its spread. Foods high in asparagine include dairy and meat products, while fruits and vegetables are low in this compound.
Researchers at Boston University School of Medicine have found that individual BET bromodomain proteins work independently, reducing the effectiveness of pan-BET inhibitors. This discovery paves the way for more fine-tuned experiments and treatments in breast cancer patients with varying levels of protein expression.
Researchers found that restricting asparagine production in mice greatly reduced breast cancer's ability to spread, suggesting a potential new treatment approach. The study also suggests that dietary changes may help stop cancer from spreading and improve outcomes for patients.
Research found that women with estrogen receptor-negative breast cancer had an increased risk of preterm birth and low birth weight compared to those with other types. The study also showed a lower birth rate among breast cancer survivors, with only about 8% having children by 10 years after diagnosis.
A new study from Ohio State University found that women whose family members or friends died of cancer are more likely to approach breast cancer prevention aggressively. Women with traumatic experiences perceive breast cancer as a death sentence, while those with positive experiences see it as a hardship that can be overcome.
Researchers have found that the loss of a tumor suppressor in triple-negative breast cancer provides clues for novel treatments. Drugs targeting PLK1, AURK and CHK1 may be effective for 20-30% of patients with RB-deficient tumors.
Researchers identified unique mitochondrial defects and alterations in metabolic gene expression associated with aggressive triple-negative breast cancers. The findings provide new molecular biomarkers to identify patients at risk for metastasis and offer potential therapeutic targets.
A new scientific statement highlights the interconnection between cardiovascular disease and breast cancer, emphasizing the need for research and specialized treatment. The American Heart Association emphasizes prevention and modification of cardiac risk factors during and after breast cancer treatment.
Researchers Jos Jonkers and Helen Piwnica-Worms receive a grant to investigate how the immune system recognizes breast cancer. They will use imaging mass cytometry and patient-derived models to devise new treatment combinations, accelerating promising therapies to patients.
New scientific statement highlights potential heart damage from breast cancer treatments and suggests strategies to minimize risks. Lifestyle choices, such as diet and exercise, can also help decrease the risks of developing both diseases.
A nationwide population-based study analyzed over 120,000 women diagnosed with early-stage breast cancer, finding that only 14.7% required additional biopsies during follow-up care. The study's findings will help physicians counsel patients about breast cancer recurrence rates and the need for future biopsies.
Researchers at Stanford University School of Medicine developed a cancer vaccine that eliminates tumors in mice by stimulating immune cells within the tumor site. The treatment showed promise for many types of cancers and could potentially replace or complement existing immunotherapy approaches.
A new interactive online tool helps breast cancer patients better understand their treatment options, resulting in higher knowledge and preparedness. The tool assesses patients' values and provides a customized bar graphic to guide decision-making.
Researchers at Moffitt Cancer Center have discovered a new way to stimulate the immune system to target cancer cells. The study found that activating dendritic cells with a TIM-3 antibody indirectly stimulates T cell anti-cancer activity, leading to reduced tumor growth in mice.
A study published in Plastic and Reconstructive Surgery found that direct-to-implant (DTI) breast reconstruction in women over 65 resulted in good outcomes, including similar complication rates to tissue expander implant (TEI) reconstruction. The DTI approach also showed fewer hospital readmissions and reduced total hospital stay days.
Huntsman Cancer Institute has been selected as a NCI Center for patient-derived model development, utilizing cutting-edge research to test new drugs and drug combinations for breast cancer. The goal is to provide data to prioritize clinical trials and help determine why certain drugs work for some people and others do not.
Research finds that postmenopausal women with higher body fat levels, even those with a normal BMI, have an increased risk of invasive breast cancer. Dual energy X-ray absorptiometry (DXA) measurements show that whole body fat levels are more accurately assessed than traditional BMI methods.
A University of Guelph study found that omega-3s from fish are eight times more effective at inhibiting tumour development and growth compared to plant-based options. The research suggests that marine-derived omega-3s can significantly reduce breast cancer risk, particularly in aggressive forms.
Researchers at the University of Liverpool have found that macrophages express insulin-like growth factors (IGFs) 1 and 2, which support breast cancer metastasis. The study suggests a significant reduction in tumour cell growth and lung metastasis when IGFs are blocked with paclitaxel.
Researchers at Washington University School of Medicine have developed a novel technique using nanoparticles and light to target and kill metastatic cancer cells. The technique, which harnesses the power of chemotherapy drugs and radiation, shows promise in treating multiple myeloma and aggressive breast cancer.
Researchers at Mayo Clinic developed a new test that can establish which inherited BRCA2 gene mutations increase the risk of breast or ovarian cancer. The study identified 54 pathogenic mutations and expanded the list of neutral mutations, providing better decision-making options for patients with genetic testing results.
Yale Cancer Center investigators developed a new statistical model to assess patient risk for cancer, which can result in more efficient and effective clinical trials. This approach can guarantee that the statistical power of the study is adequate to demonstrate if a new treatment is effective.
Researchers have found that blocking production of the chemical 20-HETE can control glioblastoma and breast cancer growth. The inhibitor HET0016 reduced tumor aggressiveness and invasiveness, slowing disease progression.
A team of scientists has identified the protein kinase MSK1 as a key regulator of dormant or latent metastases in estrogen-positive breast cancer. The study found that tumors expressing MSK1 have a longer period of latency with no symptoms, reducing the risk of earlier relapse.
A USC study suggests that regular exercise can lower breast cancer survivors' risk of cardiovascular disease, Type 2 diabetes, and breast cancer recurrence. Exercise helps reduce inflammation, improves heart health, and increases good cholesterol levels.
Researchers found that combining temozolomide with the enzyme inhibitor SLC-0111 significantly regressed human-derived glioblastoma, improving patient outcomes. The treatment strategy targets carbonic anhydrase 9, a membrane enzyme involved in tumor growth.
Women with MSH6 and PMS2 gene variants have a 2-fold or 3-fold increased risk of developing breast cancer. The study suggests more intensive screening for these women may be beneficial.
A study published in The Journal of the National Cancer Institute found that patients with high intra-tumour heterogeneity of the oestrogen receptor are twice as likely to die from breast cancer over a span of 25 years. This risk holds true for Luminal A breast cancer subtype, which is generally considered to have a good prognosis.
Researchers identified two new breast cancer genes MSH6 and PMS2, associated with a doubled risk of developing breast cancer by age 60. The study suggests expanding genetic screening for these genes in women with Lynch syndrome.
A new Michigan State University study finds that mice can mimic human breast cancer tissue and genes, as well as other cancers including lung, oral, and esophagus. This breakthrough could lead to more effective treatments by identifying similarities between tumors.
A study found that screening the general population for cancer genes is cost-effective, preventing more breast and ovarian cancers. This approach could lead to thousands fewer cases of these cancers, particularly among women over 30.
After the Affordable Care Act eliminated cost sharing for screening mammograms, mammogram rates increased six percentage points among older women, according to a Brown University study. The study found that eliminating copayments led to an increase in their use and was concentrated among women with more education.
Researchers found that population testing for multiple cancer genes is the most cost-effective strategy, preventing many more ovarian and breast cancers than current screening methods. This approach could save thousands of lives by reducing risk factors through enhanced screening, medical prevention, or risk-reducing surgery.